NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
160
NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE

NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFN alpha KINOID IN THE TREATMENT OF LUPUS WHICH ALLOWS TO PROCEED WITH THE CLINICAL DEVELOPMENT INTO PHASE III

THE BIOLOGICAL OBJECTIVE AND THREE OUT OF FOUR CLINICAL OBJECTIVES WERE MET:

  • Highly statistically significant efficacy in reduction of interferon signature
  • Lack of statistically significant clinical efficacy measured by BICLA [1] score
  • Statistical trend on clinical efficacy measured by SRI-4 [2]   with reduction of steroid less than or equal to 5mg/day
  • Statistically significant clinical efficacy on the LLDAS [3] score
  • Favorable safety profile of IFNalpha Kinoid treatment

Paris and Boston, July 3, 2018 - 7:00 am CEST - Neovacs (Euronext Growth Paris: ALNEV ), a leader in active immunotherapy for the treatment of autoimmune diseases, today announces the results of its Phase IIb clinical trial of IFNalpha Kinoid in patients with moderate to severe lupus (SLE).

The results show a very statistically significant biological efficacy of IFNalpha Kinoid (p <0.0001), measured by the decrease of the interferon signature at week 36 of the study. The clinical response in patients treated with IFNalpha Kinoid vs those treated with placebo measured by the BICLA score at week 36, did not achieve a statistical trend as defined in the primary objectives of the study.

" It is important to note the very marked effect of IFNalpha Kinoid on the LLDAS score, of which one of the 5 criteria is the reduction of steroid use ," stressed Professor Frédéric Houssiau, Scientific Chairman of the study, Rheumatology Department, Saint-Luc Clinical Universities, Brussels, Belgium . It suggests that one must take into account the reduction of steroid therapy , an important goal of treatment. This study demonstrates, once again, the difficulties in choosing the primary clinical endpoint in SLE."

The main secondary endpoints for assessing clinical efficacy were:

  • SRI-4 with steroid reduction less than or equal to 5 mg/day
  • LLDAS (Lupus Low Disease Activity Score)

Measured in week 36, SRI-4 with a reduction of steroid to less than or equal to 5mg/day showed a statistical trend of 54.4% for treated patients vs. 39% in those treated with placebo (p = 0.07) and the LLDAS a statistically significant effect of 52.9% vs. 29.8% (p = 0.002). Both point in favor of IFNalpha Kinoid treatment, which coupled with a major reduction in steroid is an important therapeutic step forward .

IFN alpha Kinoid was well tolerated and serious adverse events were reported more frequently in the placebo group (12.9%) compared to the IFNalpha Kinoid treated group (6.6%).

" These results of clinical efficacy, in particular on two reference indices (SRI-4 with steroid reduction to less than or equal to 5 mg/day and LLDAS ) which have been validated by international health authorities or medical community, authorise the further clinical development with these scores into phase III ," said Thérèse Croughs MD, Chief Medical Officer of Neovacs. " We would like to express our thanks to the patients, the investigators and all those who contributed to this important Phase IIb trial of our therapeutic vaccine in lupus ."

This double blind, randomized, placebo-controlled, multi-center, Phase IIb study enrolled 185 patients in Europe, Asia, the United States, North Africa, and Latin America with moderate to severe lupus. The primary endpoints for the trial were biological efficacy and clinical efficacy nine months after the first treatment with IFNalpha Kinoid. Patients were randomized to receive either IFNalpha Kinoid or placebo intramuscular 5 times: days 1, 7, and 28 and then at 3 and 6 months. Patients also received standard treatment with antimalarials, immunosuppressants and / or steroids, the latest were gradually decreased to a dose less than or equal to 5 mg of prednisolone equivalent / day by 24 weeks and remained stable until the 36th week. At the end of this primary evaluation period, patients entered a 5-year follow-up period to assess the safety as well as the long-term biological and clinical efficacy of IFNalpha Kinoid.

" We are very pleased with these results that will enable us to move into phase III within a partnering to be finalised, in line with the objectives announced previously ," said Miguel Sieler Chief Executive Officer of Neovacs, adding, " We have achieved 4 major objectives in a complex autoimmune disease . These results confirm the relevance of our innovative therapeutic approach and strengthen the potential of Kinoid treatment . "

Neovacs plans to submit the full results of this study and present them at a future international scientific congress.

The U.S. Food and Drug Administration has already granted Fast Track Status for IFNalpha Kinoid in lupus to Neovacs.

Neovacs will hold a Webcast conference call today at 10:00 am CEST, log in via the following link: https://channel.royalcast.com/webcast/neovacsfr/20180703_2/

For more information, visit this phase IIb clinical study with IFNalpha Kinoid in the treatment of lupus: www.clinicaltrial.gov. (Identifier: NCT02665364)

About Lupus Systemic lupus erythematosus (SLE) or lupus erythematosus is a debilitating, chronic autoimmune disease whose etiology remains unknown. SLE is characterized by a loss of tolerance of self-antigens, with the production of autoantibodies, especially antinuclear antibodies that attack healthy tissues and cause inflammatory reactions in different parts of the body. The disease can affect multiple organs (skin, kidneys, joints, heart, lungs, central nervous system, etc.) and is characterized by heterogeneous clinical signs (skin rashes, arthritis, photosensitivity, nephritis, neurological disorders, anemia, thrombocytopenia, etc.), which vary from one person to another and change during the progression of the disease. Systemic lupus erythematosus affects mostly women.

About IFN alpha Kinoide

Neovacs anti-IFNalpha therapy consists of patient immunization using Interferon alpha (IFNalpha) kinoid (IFNalpha Kinoid). IFNalpha Kinoid is a heterocomplex consisting of an inactivated IFNalpha coupled to a T-helper stimulating carrier protein, Keyhole Limpet Hemocyanin (KLH). IFN-K is emulsified with Montanide(TM) oily adjuvant that non-specifically stimulates cell-mediated immune (CMI) responses to antigens.

IFNalpha Kinoid elicits the production of neutralizing polyclonal antibodies directed against the excess IFNalpha, thus blocking its ability to activate the inflammatory cascade. The generation of polyclonal neutralizing antibodies against IFNalpha following the administration of IFNalpha Kinoid is relevant to diseases mediated by IFNalpha over-production, such as Systemic Lupus Erythematosus (SLE), Dermatomyositis (DM), Type I Diabetes (T1D) and Sjögren's Syndrome (SS).

About Neovacs Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of autoimmune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr

Contacts

NEOVACS - Corporate Communication & Investor Relations Charlène Masson +33 1 53 10 93 00 cmasson@neovacs.com

LIFESCI ADVISORS - Investor Relations / Financial Communications Chris Maggos +41 79 367 6254 chris@lifesciadvisors.com

[1] BILAG-Based Composite Lupus Assessment score

[2] Systemic Lupus Erythematosus Responder Index-4 with a reduction at less than or equal to 5mg/day level of glucocorticoids less than or equal to 5mg/day

[3] Lupus Low Disease Activity State

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LONGWELL's New Axial Fan Selection Guide Unveiled

Updated Category News Views 51

LONGWELL's New Fan Brochure Shakes Up Data Center Cooling Alright, let's cut to the chase. LONGWELL, the folks out in Ningbo who live and breathe HVACR and industrial fans, have dropped a new tool that’s going to have OEM engineers raising a glass. This twelve-page axial fan selection guide is a stroke of genius—or at least that's what those of us who've braved the...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 53

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 21

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 122

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
WHP Global's Japan Move: A Major Toy Market Play

Updated Category News Views 0

New Horizons for Toys"R"Us in Japan Well, folks, look who's back in the toy game with a vengeance! WHP Global is shaking hands with Pan Pacific International Holdings (PPIH) to breathe new life into Toys"R"Us across Japan. Now PPIH isn’t just any player. We're talking about Japan's fourth-largest retailer, helming giants like Don Quijote and aiming to crown itself as...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 86

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 27

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 101

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 50

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating a Milestone: Gifting the 400th Home to a Veteran

Updated Category News Views 339

Celebrating a Milestone with 400th Home Gift Building Homes for Heroes and Hillwood Properties proudly partnered to celebrate a significant milestone by gifting a home to U.S. Army Specialist Joshua Sager and his family. This remarkable achievement signifies the organization’s commitment to providing veterans and first responders with the means to establish a fresh...

Continue Reading
Wheeler REIT Achieves Record Price as Growth Continues

Updated Category News Views 259

Wheeler REIT Reaches New Milestone In an extraordinary demonstration of resilience and upward momentum, Wheeler Real Estate Investment Trust (WHLRD) has achieved a remarkable milestone by hitting a 52-week high of $27.49 USD. This achievement reflects the company's strong performance and investor confidence in its strategic direction. Strong Financial Position Recent data...

Continue Reading
S&P Global Splits Off Mobility Unit: Investor View

Updated Category News Views 52

Strategic Moves Shake Up S&P Global Listen up, traders! You don’t want to miss what S&P Global, ticker NYSE:SPGI, is cooking up. They've given the green light to split off their Mobility division, officially birthing Mobility Global Inc. This shake-up promises to stir some excitement in the market. Buckle up, because here's what this movement means for you and your...

Continue Reading
Carvana's Q3 Earnings Surge Promises Bright Future for CVNA

Updated Category News Views 103

Carvana Shares Soar After Impressive Q3 Earnings Report Recently, Carvana (NYSE: CVNA), a leading online used-car retailer, experienced a significant surge in its stock price as a result of a positive earnings announcement for the third quarter. The encouraging outlook provided by the company has delighted investors, pushing shares upward during premarket trading....

Continue Reading
PHINIA Unveils Comprehensive Guide to International Emission Standards

Updated Category News Views 150

PHINIA Unveils New Emission Standards Guide for 2024/25 PHINIA Inc. (NYSE: PHIN), a leading name in premium fuel systems and electrical solutions, has launched its latest 2024/25 Emission Standards Booklet specifically designed for heavy-duty and off-road vehicles, engines, and machinery. This guide is unique as it serves as the only complete resource available to keep...

Continue Reading